Table 5.

Covariates predictive of shorter survival among patients given gemtuzumab ozogamicin (GO) with or without interleukin 11 (IL-11; n = 51) or idarubicin plus cytosine arabinoside (n = 31)

CovariatePosterior mean (SD)Posterior probability of harmful effect
Performance status 3 or 4 0.672  (0.241) 0.996  
Treatment in laminar-airflow room −0.969  (0.206) 0.000  
Cytogenetic finding of −5/−7 1.230  (0.239) 1.000  
Other cytogenetic abnormalities 0.679  (0.234) 0.998  
Treatment with GO with or without IL-11 0.823  (0.323) 0.995 
CovariatePosterior mean (SD)Posterior probability of harmful effect
Performance status 3 or 4 0.672  (0.241) 0.996  
Treatment in laminar-airflow room −0.969  (0.206) 0.000  
Cytogenetic finding of −5/−7 1.230  (0.239) 1.000  
Other cytogenetic abnormalities 0.679  (0.234) 0.998  
Treatment with GO with or without IL-11 0.823  (0.323) 0.995